FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4386475128> ?p ?o ?g. }

• W4386475128 abstract "Isoxazole belongs to the class of five-membered heterocyclic compounds. The process of developing new drugs has significantly gained attention due to inadequate pharmacokinetic and safety attributes of the available drugs. This study aimed to design a new diverse array of ten novel isoxazole derivatives via Claisen Schmidt condensation reaction. In vitro COX-1/2 anti-inflammatory assay, in silico molecular docking of potent compounds, Molecular docking simulation, and SwissADME pharmacokinetic profile were investigated in this research. The in vitro COX-1 and COX-2 enzyme inhibitory assay showed that almost all the tested compounds exhibited anti-inflammatory effects whereas C6, C5, and C3 were found to be the most potent COX-2 enzyme inhibitors among the tested compounds and are good candidates for selective COX-2 inhibitors. In silico molecular docking studies coupled with molecular dynamic simulation has been done to rationalize the time-evolved mode of interaction of selected inhibitor inside the active pockets of target COX-2. The binding orientations and binding energy results also showed the selectivity of compounds towards COX-2. Physicochemical properties, pharmacokinetic profile, lipophilicity, water solubility, drug metabolism, drug-likeness properties, and medicinal chemistry of the synthesized isoxazole derivatives were assessed. The SwissADME (absorption, distribution, metabolism, and excretion) database was used to assess the physicochemical properties and drug-likeness properties of the synthesized isoxazole derivatives. All the compounds were shown high GI absorption except Compound 7 (C7). Compound 1 (C1) and Compound 2 (C2) were found to cross the blood-brain barrier (BBB). Lipinski's rule of five is not violated by any of the ten synthesized isoxazole derivatives. It was predicted with the SwissADME database that C2, C5, C6, C7, and C8 are potent inhibitors of cytochrome (CYP) subtype CYP-2C19. A subtype of CYP-2C9 was inhibited by C4 and C7. The medicinal chemistry of all the compounds C1-C10 showed no PAIN (Pan assay interference compounds) alerts. The improved gastrointestinal (GI) absorption and BBB permeability of C1 and C2 can provide a future prospective for new researchers in the medicinal field to investigate the compounds for the management of chronic diseases. The synthesized isoxazole compounds showed excellent in vitro COX-1/2 enzymes anti-inflammatory investigations, in silico studies, good physicochemical properties, and improved pharmacokinetic profile which will be further investigated via in vivo anti-inflammatory activities. Moreover, to further support our findings of the computational research and in vitro studies, an in-vivo pharmacokinetic profile is suggested in the future." @default.
• W4386475128 created "2023-09-07" @default.
• W4386475128 creator A5015562906 @default.
• W4386475128 creator A5033532148 @default.
• W4386475128 creator A5061582383 @default.
• W4386475128 creator A5080863911 @default.
• W4386475128 creator A5085120624 @default.
• W4386475128 creator A5085334707 @default.
• W4386475128 date "2023-09-06" @default.
• W4386475128 modified "2023-10-16" @default.
• W4386475128 title "Synthesis, in-vitro inhibition of cyclooxygenases and in silico studies of new isoxazole derivatives" @default.
• W4386475128 cites W1479760463 @default.
• W4386475128 cites W1964437706 @default.
• W4386475128 cites W1981708439 @default.
• W4386475128 cites W1981737096 @default.
• W4386475128 cites W1983197888 @default.
• W4386475128 cites W1984943087 @default.
• W4386475128 cites W1994727418 @default.
• W4386475128 cites W1999208772 @default.
• W4386475128 cites W1999686489 @default.
• W4386475128 cites W2010916187 @default.
• W4386475128 cites W2014637600 @default.
• W4386475128 cites W2017205892 @default.
• W4386475128 cites W2025437922 @default.
• W4386475128 cites W2028978816 @default.
• W4386475128 cites W2039478311 @default.
• W4386475128 cites W2059737570 @default.
• W4386475128 cites W2081822067 @default.
• W4386475128 cites W2083748640 @default.
• W4386475128 cites W2085067780 @default.
• W4386475128 cites W2094113243 @default.
• W4386475128 cites W2094750196 @default.
• W4386475128 cites W2105649494 @default.
• W4386475128 cites W2113364934 @default.
• W4386475128 cites W2129094690 @default.
• W4386475128 cites W2157224913 @default.
• W4386475128 cites W2256824405 @default.
• W4386475128 cites W2286394330 @default.
• W4386475128 cites W2310460235 @default.
• W4386475128 cites W2401695560 @default.
• W4386475128 cites W2544955439 @default.
• W4386475128 cites W2554458703 @default.
• W4386475128 cites W2555563134 @default.
• W4386475128 cites W2593436234 @default.
• W4386475128 cites W2742661340 @default.
• W4386475128 cites W2747315313 @default.
• W4386475128 cites W2752400704 @default.
• W4386475128 cites W2776264081 @default.
• W4386475128 cites W2790725892 @default.
• W4386475128 cites W2806424166 @default.
• W4386475128 cites W2892113269 @default.
• W4386475128 cites W2897320736 @default.
• W4386475128 cites W2920078889 @default.
• W4386475128 cites W2949385702 @default.
• W4386475128 cites W2949664011 @default.
• W4386475128 cites W2950351633 @default.
• W4386475128 cites W2951576022 @default.
• W4386475128 cites W2982716509 @default.
• W4386475128 cites W2985636042 @default.
• W4386475128 cites W3007717088 @default.
• W4386475128 cites W3091980736 @default.
• W4386475128 cites W3157784408 @default.
• W4386475128 cites W3159354419 @default.
• W4386475128 cites W3204273079 @default.
• W4386475128 cites W3211858634 @default.
• W4386475128 cites W3215815646 @default.
• W4386475128 cites W4200187293 @default.
• W4386475128 cites W4224083899 @default.
• W4386475128 cites W4239444816 @default.
• W4386475128 cites W4283585996 @default.
• W4386475128 cites W4284884042 @default.
• W4386475128 cites W4306155844 @default.
• W4386475128 cites W583732574 @default.
• W4386475128 doi "https://doi.org/10.3389/fchem.2023.1222047" @default.
• W4386475128 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37744065" @default.
• W4386475128 hasPublicationYear "2023" @default.
• W4386475128 type Work @default.
• W4386475128 citedByCount "0" @default.
• W4386475128 crossrefType "journal-article" @default.
• W4386475128 hasAuthorship W4386475128A5015562906 @default.
• W4386475128 hasAuthorship W4386475128A5033532148 @default.
• W4386475128 hasAuthorship W4386475128A5061582383 @default.
• W4386475128 hasAuthorship W4386475128A5080863911 @default.
• W4386475128 hasAuthorship W4386475128A5085120624 @default.
• W4386475128 hasAuthorship W4386475128A5085334707 @default.
• W4386475128 hasBestOaLocation W43864751281 @default.
• W4386475128 hasConcept C104317684 @default.
• W4386475128 hasConcept C112705442 @default.
• W4386475128 hasConcept C159110408 @default.
• W4386475128 hasConcept C178910836 @default.
• W4386475128 hasConcept C181199279 @default.
• W4386475128 hasConcept C185592680 @default.
• W4386475128 hasConcept C201399114 @default.
• W4386475128 hasConcept C202751555 @default.
• W4386475128 hasConcept C21951064 @default.
• W4386475128 hasConcept C2775905019 @default.
• W4386475128 hasConcept C2781269603 @default.
• W4386475128 hasConcept C41685203 @default.
• W4386475128 hasConcept C41847442 @default.
• W4386475128 hasConcept C55493867 @default.

• next